Evotec (EVO) Set to Announce Quarterly Earnings on Thursday

Evotec (NASDAQ:EVO) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.1783) per share and revenue of $165.01 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Evotec Stock Up 3.0%

NASDAQ:EVO opened at $1.56 on Tuesday. Evotec has a 1 year low of $1.33 and a 1 year high of $4.09. The business has a 50 day simple moving average of $1.64 and a 200-day simple moving average of $2.52. The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on EVO. TD Cowen downgraded Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a research report on Wednesday, July 15th. Weiss Ratings downgraded Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 25th. Berenberg Bank lowered shares of Evotec from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Evotec in a research report on Wednesday, October 14th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Evotec currently has an average rating of “Hold” and a consensus target price of $3.00.

Evotec Company Profile

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.